PMC3196279

Cannabis diagnosis was the most prevalent substance use disorder across all age, sex, racial/ethnic, and treatment setting groups among youth psychiatric patients, accounting for more than 80% of all

Effect: decline; Cannabis SUD 10.4% of all patients; >80% of all SUD cases; 21.2% among ages 13-17

Cannabis diagnosis was the most prevalent substance use disorder across all age, sex, racial/ethnic, and treatment setting groups among youth psychiatric patients, accounting for more than 80% of all

Effect: decline; Cannabis SUD 10.4% of all patients; >80% of all SUD cases; 21.2% among ages 13-17

Cannabis diagnosis was the most prevalent substance use disorder across all age, sex, racial/ethnic, and treatment setting groups among youth psychiatric patients, accounting for more than 80% of all

Effect: decline; Cannabis SUD 10.4% of all patients; >80% of all SUD cases; 21.2% among ages 13-17

Cannabis diagnosis was the most prevalent substance use disorder across all age, sex, racial/ethnic, and treatment setting groups among youth psychiatric patients, accounting for more than 80% of all

Effect: decline; Cannabis SUD 10.4% of all patients; >80% of all SUD cases; 21.2% among ages 13-17

Cannabis diagnosis was the most prevalent substance use disorder across all age, sex, racial/ethnic, and treatment setting groups among youth psychiatric patients, accounting for more than 80% of all

Effect: decline; Cannabis SUD 10.4% of all patients; >80% of all SUD cases; 21.2% among ages 13-17

Cannabis diagnosis was the most prevalent substance use disorder across all age, sex, racial/ethnic, and treatment setting groups among youth psychiatric patients, accounting for more than 80% of all

Effect: decline; Cannabis SUD 10.4% of all patients; >80% of all SUD cases; 21.2% among ages 13-17

Cannabis diagnosis was the most prevalent substance use disorder across all age, sex, racial/ethnic, and treatment setting groups among youth psychiatric patients, accounting for more than 80% of all

Effect: decline; Cannabis SUD 10.4% of all patients; >80% of all SUD cases; 21.2% among ages 13-17

Cannabis diagnosis was the most prevalent substance use disorder across all age, sex, racial/ethnic, and treatment setting groups among youth psychiatric patients, accounting for more than 80% of all

Effect: decline; Cannabis SUD 10.4% of all patients; >80% of all SUD cases; 21.2% among ages 13-17

Cannabis diagnosis was the most prevalent substance use disorder across all age, sex, racial/ethnic, and treatment setting groups among youth psychiatric patients, accounting for more than 80% of all

Effect: decline; Cannabis SUD 10.4% of all patients; >80% of all SUD cases; 21.2% among ages 13-17

Cannabis diagnosis was the most prevalent substance use disorder across all age, sex, racial/ethnic, and treatment setting groups among youth psychiatric patients, accounting for more than 80% of all

Effect: decline; Cannabis SUD 10.4% of all patients; >80% of all SUD cases; 21.2% among ages 13-17

Cannabis diagnosis was the most prevalent substance use disorder across all age, sex, racial/ethnic, and treatment setting groups among youth psychiatric patients, accounting for more than 80% of all

Effect: decline; Cannabis SUD 10.4% of all patients; >80% of all SUD cases; 21.2% among ages 13-17

Cannabis diagnosis was the most prevalent substance use disorder across all age, sex, racial/ethnic, and treatment setting groups among youth psychiatric patients, accounting for more than 80% of all

Effect: decline; Cannabis SUD 10.4% of all patients; >80% of all SUD cases; 21.2% among ages 13-17

Cannabis diagnosis was the most prevalent substance use disorder across all age, sex, racial/ethnic, and treatment setting groups among youth psychiatric patients, accounting for more than 80% of all

Effect: decline; Cannabis SUD 10.4% of all patients; >80% of all SUD cases; 21.2% among ages 13-17

Cannabis diagnosis was the most prevalent substance use disorder across all age, sex, racial/ethnic, and treatment setting groups among youth psychiatric patients, accounting for more than 80% of all

Effect: decline; Cannabis SUD 10.4% of all patients; >80% of all SUD cases; 21.2% among ages 13-17

Cannabis diagnosis was the most prevalent substance use disorder across all age, sex, racial/ethnic, and treatment setting groups among youth psychiatric patients, accounting for more than 80% of all

Effect: decline; Cannabis SUD 10.4% of all patients; >80% of all SUD cases; 21.2% among ages 13-17

Cannabis diagnosis was the most prevalent substance use disorder across all age, sex, racial/ethnic, and treatment setting groups among youth psychiatric patients, accounting for more than 80% of all

Effect: decline; Cannabis SUD 10.4% of all patients; >80% of all SUD cases; 21.2% among ages 13-17

Cannabis diagnosis was the most prevalent substance use disorder across all age, sex, racial/ethnic, and treatment setting groups among youth psychiatric patients, accounting for more than 80% of all

Effect: decline; Cannabis SUD 10.4% of all patients; >80% of all SUD cases; 21.2% among ages 13-17

Cannabis diagnosis was the most prevalent substance use disorder across all age, sex, racial/ethnic, and treatment setting groups among youth psychiatric patients, accounting for more than 80% of all

Effect: decline; Cannabis SUD 10.4% of all patients; >80% of all SUD cases; 21.2% among ages 13-17

Cannabis diagnosis was the most prevalent substance use disorder across all age, sex, racial/ethnic, and treatment setting groups among youth psychiatric patients, accounting for more than 80% of all

Effect: decline; Cannabis SUD 10.4% of all patients; >80% of all SUD cases; 21.2% among ages 13-17

Cannabis diagnosis was the most prevalent substance use disorder across all age, sex, racial/ethnic, and treatment setting groups among youth psychiatric patients, accounting for more than 80% of all

Effect: decline; Cannabis SUD 10.4% of all patients; >80% of all SUD cases; 21.2% among ages 13-17

Cannabis diagnosis was the most prevalent substance use disorder across all age, sex, racial/ethnic, and treatment setting groups among youth psychiatric patients, accounting for more than 80% of all

Effect: decline; Cannabis SUD 10.4% of all patients; >80% of all SUD cases; 21.2% among ages 13-17

Cannabis diagnosis was the most prevalent substance use disorder across all age, sex, racial/ethnic, and treatment setting groups among youth psychiatric patients, accounting for more than 80% of all

Effect: decline; Cannabis SUD 10.4% of all patients; >80% of all SUD cases; 21.2% among ages 13-17

Cannabis diagnosis was the most prevalent substance use disorder across all age, sex, racial/ethnic, and treatment setting groups among youth psychiatric patients, accounting for more than 80% of all

Effect: decline; Cannabis SUD 10.4% of all patients; >80% of all SUD cases; 21.2% among ages 13-17

Cannabis diagnosis was the most prevalent substance use disorder across all age, sex, racial/ethnic, and treatment setting groups among youth psychiatric patients, accounting for more than 80% of all

Effect: decline; Cannabis SUD 10.4% of all patients; >80% of all SUD cases; 21.2% among ages 13-17

Cannabis diagnosis was the most prevalent substance use disorder across all age, sex, racial/ethnic, and treatment setting groups among youth psychiatric patients, accounting for more than 80% of all

Effect: decline; Cannabis SUD 10.4% of all patients; >80% of all SUD cases; 21.2% among ages 13-17

Cannabis diagnosis was the most prevalent substance use disorder across all age, sex, racial/ethnic, and treatment setting groups among youth psychiatric patients, accounting for more than 80% of all

Effect: decline; Cannabis SUD 10.4% of all patients; >80% of all SUD cases; 21.2% among ages 13-17

Cannabis diagnosis was the most prevalent substance use disorder across all age, sex, racial/ethnic, and treatment setting groups among youth psychiatric patients, accounting for more than 80% of all

Effect: decline; Cannabis SUD 10.4% of all patients; >80% of all SUD cases; 21.2% among ages 13-17

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%